Dr. Baljevic is leading institutional effort to develop safety and efficacy track record of utilizing remote monitoring wearables for the full outpatient delivery of bispecific antibodies in MM (currently unexplored area in the field). He is a frequent invitee as a discussion leader, moderator, consultant, lecturer or a committee expert member (recently multi study co-chair) on an independent review committees for adjudication of MM international and national clinical trials.